Cargando…

Impact of mitochondrial DNA mutations in multiple myeloma

Detalles Bibliográficos
Autores principales:	Hoang, Phuc H., Cornish, Alex J., Chubb, Daniel, Jackson, Graham, Kaiser, Martin, Houlston, Richard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195394/ https://www.ncbi.nlm.nih.gov/pubmed/32358481 http://dx.doi.org/10.1038/s41408-020-0315-4

Ejemplares similares

Mutational processes contributing to the development of multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2019)

Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms
por: Hoang, Phuc H., et al.
Publicado: (2018)

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
por: Hoang, Phuc H., et al.
Publicado: (2020)

Reference bias in the Illumina Isaac aligner
por: Cornish, Alex J, et al.
Publicado: (2020)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Exploiting gene dependency to inform drug development for multiple myeloma
por: Went, Molly, et al.
Publicado: (2022)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report
por: Shah, Vallari, et al.
Publicado: (2017)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
por: Evers, Marietheres, et al.
Publicado: (2023)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Durable response of multiple myeloma and non‐small cell lung cancer with simultaneous, biologically targeted treatment
por: Kaiser, Martin F., et al.
Publicado: (2020)

Regions of homozygosity as risk factors for multiple myeloma
por: Went, Molly, et al.
Publicado: (2019)

Search for rare protein altering variants influencing susceptibility to multiple myeloma
por: Scales, Matthew, et al.
Publicado: (2017)

Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes
por: Studd, James B., et al.
Publicado: (2021)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

Late-onset mitochondrial disease in a patient with MELAS and mitochondrial DNA T14487C mutation
por: Xu, Xue-Bi, et al.
Publicado: (2019)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
por: Liu, Zhao-Yun, et al.
Publicado: (2023)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023)

Brain atrophy in a patient with mitochondrial DNA G8363A mutation
por: Xu, Hong-Liang, et al.
Publicado: (2019)

Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2019)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Characterization of rare germline variants in familial multiple myeloma
por: Catalano, Calogerina, et al.
Publicado: (2021)

Sensitive multiple myeloma disease monitoring by mass spectrometry
por: Santockyte, Rasa, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
por: Chiu, Brian C.-H., et al.
Publicado: (2022)

Identification of novel genetic loci for risk of multiple myeloma by functional annotation
por: Macauda, Angelica, et al.
Publicado: (2023)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Multiple myeloma: family history and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

IgA Type Multiple Myeloma, Clinical Features, and Prognosis
por: Wang, Ling, et al.
Publicado: (2018)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Orbital and Choroidal Plasmacytoma in Recurrent Multiple Myeloma: A Case Report
por: Choi, Ji Ho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tur9nvp2ok5vsdkfa7fg5i2nrs